Malignant Transformation of Monoclonal Gammopathy of Undetermined Significance: Cumulative Incidence and Prognostic Factors

References

• Axelson U. A 20-Year Follow-up Study of 64 Subjects with M-components. Acta Medica Scandinavica 1986; 219: 519–522
   PubMed Web of Science ®Google Scholar
• Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Implications for progression to overt multiple myeloma. Hematology/Oncology Clinics of North America 1997; 11(1)71–87
   PubMed Web of Science ®Google Scholar
• Kyle RA. Benign monoclonal gammopathy–after 20 to 35 years of follow-up. Mayo Clinic Proceedings 1993; 68(1)26–36
   PubMed Web of Science ®Google Scholar
• Witzig T E, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. British Journal of Haematology 1999; 104(1)131–137
   PubMed Web of Science ®Google Scholar
• Greipp P R, Kyle RA. Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Blood 1983; 62(1)166–171
   PubMed Web of Science ®Google Scholar
• Greipp P R, Witzig T E, Gonchoroff N J, Habermann T M, Katzmann J A, O'Fallon W M, Kyle RA. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clinic Proceedings 1987; 62(11)969–977
   PubMed Web of Science ®Google Scholar
• Baldini L, Guffanti A, Cesana B M, Colombi M, Chiorboli O, Damilano I, Maiolo AT. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 1996; 87(3)912–918
   PubMed Web of Science ®Google Scholar
• Isaksson E, Bjorkholm M, Holm G, Johansson B, Nilsson B, Mellstedt H, Osterborg A. Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. British Journal of Haematology 1996; 92(1)71–76
   PubMed Web of Science ®Google Scholar
• Bataille R, Chappard D, Basle MF. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies. Blood 1996; 87(11)4762–4769
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Li J Y, Morineau N, Facon T, Brigaudeau C, Harousseau J L, Grosbois B, Bataille R. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Blood 1999; 94(8)2583–2589
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp M J, Harousseau J L, Grosbois B, Bataille R. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Cancer Research 1999; 59(18)4546–4550
   PubMed Web of Science ®Google Scholar
• Greipp PR. Advances in the diagnosis and management of myeloma. Seminars in Hematology 1992; 29(3)24–45, Suppl 2
   PubMed Web of Science ®Google Scholar
• Durie BG. Staging and kinetics of multiple myeloma. Seminars in Oncology 1986; 13(3)300–309
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, Lister T A, Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology 1999; 17(12)3835–3849
   PubMed Web of Science ®Google Scholar
• Lokhorst H M, Boom S E, Bast B J, Ballieux RE. Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique. British Journal of Haematology 1986; 64(2)271–275
   PubMed Web of Science ®Google Scholar
• Lokhorst H M, Boom S E, Terpstra W, Roholl P, Gerdes J, Bast BJ. Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67. British Journal of Haematology 1988; 69(4)477–181
   PubMed Web of Science ®Google Scholar
• Blade J, Lopez-Guillermo A, Rozman C, Cervantes F, Salgado C, Aguilar J L, Vives-Corrons J L, Montserrat E. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. British Journal of Haematology 1992; 81(3)391–394
   PubMed Web of Science ®Google Scholar
• Vuckovic J, Ilic A, Knezevic N, Marinkovic M, Zemunik T, Dubravcic M. Prognosis in monoclonal gammopathy of undetermined significance. British Journal of Haematology 1997; 97(3)649–651
   PubMed Web of Science ®Google Scholar
• van de Poel M H, Coebergh J W, Hillen HF. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands. British Journal of Haematology 1995; 91(1)121–125
   PubMed Web of Science ®Google Scholar
• Greipp P R, Lust J A, O'Fallon W M, Katzmann J A, Witzig T E, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81(12)3382–3387
   PubMed Web of Science ®Google Scholar
• Lai J L, Zandecki M, Mary J Y, Bernardi F, Izydorczyk V, Flactif M, Morel P, Jouet J P, Bauters F, Facon T. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995; 85(9)2490–2497
   PubMed Web of Science ®Google Scholar
• Konigsberg R, Zojer N, Ackermann J, Kromer E, Kittler H, Fritz E, Kaufmann H, Nosslinger T, Riedl L, Gisslinger H, Jager U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. Journal of Clinical Oncology 2000; 18(4)804–812
   PubMed Web of Science ®Google Scholar
• Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, Kaufmann H, Riedl L, Gisslinger H, Schreiber S, Heinz R, Ludwig H, Huber H, Drach J. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by inter-phase fluorescence in situ hybridization. Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease. Blood 2000; 95(6)1925–1930
   PubMed Web of Science ®Google Scholar
• Konigsberg R, Zojer N, Ackermann J, Kromer E, Kittler H, Fritz E, Kaufmann H, Nosslinger T, Riedl L, Gisslinger H, Jager U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. Journal of Clinical Oncology 2000; 18(4)804–812
   PubMed Web of Science ®Google Scholar